Tag - Leerink

Markets

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Leerink slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $4 from $15, but maintained its “outperform” rating after the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary...

July 27, 2023

Executive Moves

Dr. Mani Foroohar joins Leerink research team covering therapeutics

Dr. Mani Foroohar has joined Leerink Partners’ research team as a managing director and senior research analyst covering therapeutics stocks.

May 21, 2018

Markets

Leerink resumes coverage of Sientra at OP; PT $19

Leerink resumed coverage of Sientra (NASDAQ:SIEN) with an “outperform” rating and $19 price target. The stock closed at $11.98 on April 19. Leerink suspended coverage of Sientra in 2015 following a CE Mark suspension...

April 20, 2018

Markets

Leerink cuts American Renal to MP but ups PT to $27

Leerink downgraded American Renal Associates (NYSE:ARA) to “market perform” but raised its price target to $27 from $17, citing a fuller valuation after the company reported fourth quarter results. The stock closed at...

March 8, 2018

Markets

Leerink outlines 2018 outlook of healthcare shares

Leerink is recommending that healthcare investors, after a market-beating 2017, look for ways to keep up with what will likely be a strong broader stock market in 2018. “We encourage use of higher-beta healthcare and...

December 18, 2017

Tag - Leerink

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Dr. Mani Foroohar joins Leerink research team covering therapeutics

Leerink resumes coverage of Sientra at OP; PT $19

Leerink cuts American Renal to MP but ups PT to $27

Leerink outlines 2018 outlook of healthcare shares

General

More